Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;130(4):776-784.
doi: 10.1002/jso.27904. Epub 2024 Sep 19.

Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy

Gustavo Ferreira Araruna  1 , Heber S C Ribeiro  1 , Silvio M Torres  1 , Alessandro L Diniz  1 , André L Godoy  1 , Igor C Farias  1 , Wilson L Costa Jr  2 , Felipe J F Coimbra  1
Affiliations

Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy

Gustavo Ferreira Araruna et al. J Surg Oncol. 2024 Sep.

Abstract

Background: Gastric cancer is the fifth most common neoplasm and the third leading cause of cancer-related death worldwide. Neoadjuvant chemotherapy is recommended for Stages II-III resectable tumors, but the comparative effectiveness of minimally invasive surgery (MIS) versus open gastrectomy (OG) post-neoadjuvant therapy has not been adequately investigated.

Methods: A retrospective cohort analysis was performed on patients with clinical Stage II and III gastric adenocarcinoma who underwent neoadjuvant chemotherapy followed by either MIS or OG between 2007 and 2020. Propensity score matching was utilized to compare the clinical and surgical outcomes, morbidity, and mortality, and the influence of MIS on 3-year survival rates was evaluated.

Results: After matching, no statistical differences in clinical aspects were noted between the two groups. MIS was associated with increased D2 lymphadenectomy, curative intent, and complete neoadjuvant therapy. Furthermore, this therapeutic approach resulted in reduced transfusion rates and shorter hospital stays. Nonetheless, no significant differences were observed in global, clinical, or surgical complications or mortality between the two groups. Weight loss emerged as a significant risk factor for complications, but MIS did not independently affect survival rates. Extended resection and higher American Society of Anesthesiology scores were independent predictors of reduced survival.

Conclusion: MIS after neoadjuvant chemotherapy for gastric cancer appears to be a viable option, with oncological outcomes comparable to those of OG, less blood loss, and shorter hospital stays. Although MIS did not independently affect long-term survival, it offered potential benefits in terms of postoperative recovery and morbidity. Further studies are needed to validate these findings, especially across diverse populations.

Keywords: gastric cancer; minimally invasive surgery; neoadjuvant chemotherapy; surgical outcomes.

PubMed Disclaimer

References

    1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians 61, no. 2 (March/April 2011): 69–90.
    1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer Statistics, 2014,” CA: A Cancer Journal for Clinicians 64, no. 1 (January/February 2014): 9–29.
    1. H. S. C. Ribeiro, Expressão proteica de PD‐L1 em pacientes com adenocarcinoma gástrico e de transição esôfago‐gástrica antes e após tratamento neoadjuvante e correlação com desfechos clínicos [Tese]. (São Paulo: Fundação Antônio Prudente, 2020).
    1. Japanese Gastric Cancer Association, Japanese Gastric Cancer Treatment Guidelines 2018 (5th ed),” Gastric Cancer 24 (2021): 1–21.
    1. L. C. Barchi, M. F. K. P. Ramos, A. R. Dias, et al., “Brazilian Gastric Cancer Association Guidelines: Update on Treatment,” Arquivos Brasileiros de Cirurgia Digestiva 34, no. 1 (2021): e1563.

MeSH terms

LinkOut - more resources